Nuclear Medicine and Biology
Volume 36, Issue 1 , Pages 3-10 , January 2009

Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography

  • Dale O. Kiesewetter

      Affiliations

    • Positron Emission Tomography Radiochemistry Group, NIBIB, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 301 451 3531; fax: +1 301 402 3521.
    • ,
  • Lixin Lang

      Affiliations

    • Positron Emission Tomography Radiochemistry Group, NIBIB, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Ying Ma

      Affiliations

    • Positron Emission Tomography Radiochemistry Group, NIBIB, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Abesh Kumar Bhattacharjee

      Affiliations

    • Positron Emission Tomography Radiochemistry Group, NIBIB, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Zhan-Guo Gao

      Affiliations

    • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Bhalchandra V. Joshi

      Affiliations

    • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Artem Melman

      Affiliations

    • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Sonia de Castro

      Affiliations

    • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Kenneth A. Jacobson

      Affiliations

    • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Received 29 August 2008 ,Revised 2 October 2008 ,Accepted 13 October 2008.

References 

  1. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247–264
  2. Yan L, Burbiel JC, Maass A, Muller CE. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs. 2003;8:537–576
  3. Gessi S, Cattabriga E, Avitabile A, Gafa' R, Lanza G, Cavazzini L, et al. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res. 2004;10:5895–5901
  4. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314:1792–1795
  5. Baraldi PG, Tabrizi MA, Romagnoli R, Fruttarolo F, Merighi S, Varani K, et al. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A3 adenosine receptors in human tumor cell lines. Curr Med Chem. 2005;12:1319–1329
  6. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, Fishman P. A3 adenosine receptor activation in melanoma cells — association between receptor fate and tumor growth inhibition. J Biol Chem. 2003;278:42121–42130
  7. Dixon AK, Gubitz AK, Sirinathsinghji DJS, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol. 1996;118:1461–1468
  8. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol. 2008;35:41–48
  9. Madi L, Cohen S, Ochayin A, Bar-Yehuda S, Barer F, Fishman P. Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappa B in mediating receptor level. J Rheumatol. 2007;34:20–26
  10. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, et al. The PI3K-NF-kappa B signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther. 2006;8:
  11. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol. 2005;32:469–476
  12. Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, et al. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappa B activation: a new class of myeloprotective agents. Exp Hematol. 2002;30:1390–1398
  13. Fishman P, Bar-Yehuda S, Madi L. Targeting the A3 adenosine receptor (A3AR): a new approach for cancer treatment. Drug Dev Res. 2002;56:547
  14. Fishman P, Bar-Yehuda S. Pharmacology and therapeutic applications of A(3) receptor subtype. Curr Top Med Chem. 2003;3:463–469
  15. Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res. 2004;10:4472–4479
  16. Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger A, et al. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene. 2004;23:2465–2471
  17. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, et al. Novel N-6-substituted adenosine 5′-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol. 2003;285:H2780–H2787
  18. Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y. Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res. 2006;84:1848–1855
  19. Gallo-Rodriguez C, Ji XD, Melman N, Siegman BD, Sanders LH, Orlina J, et al. Structure–activity relationships of N-6-benzyladenosine-5′-uronamides as A3-selective adenosine agonists. J Med Chem. 1994;37:636–646
  20. Guzman J, Yu JG, Suntres Z, Bozarov A, Cooke H, Javed N, et al. ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm Bowel Dis. 2006;12:766–789
  21. Hardwick MJ, Chen MK, Baidoo K, Pomper MG, Guilarte TR. In vivo imaging of peripheral benzodiazepine receptors in mouse lungs: a biomarker of inflammation. Mol Imaging. 2005;4:432–438
  22. Bauer A, Langen KJ, Bidmon H, Holschbach MH, Weber S, Olsson RA, et al. F-18-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. J Nucl Med. 2005;46:450–454
  23. Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, et al. In vivo imaging of adenosine A2A receptors in rat and primate brain using [C-11]SCH442416. Eur J Nucl Med Mol Imaging. 2005;32:405–413
  24. Gao ZG, Kim SK, Biadatti T, Chen WZ, Lee K, Barak D, et al. Structural determinants of A3 adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem. 2002;45:4471–4484
  25. Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, Jacobson KA. (N)-Methanocarba 2,N-6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem. 2005;48:1745–1758
  26. Matot I, Einav S, Weiniger CF, Pearl RG, Abramovitch R, Joshi BV, et al. Lung injury after in vivo reperfusion — outcome at 27 hours after reperfusion. Anesthesiology. 2008;109:269–278
  27. Li AH, Moro S, Forsyth N, Melman N, Ji XD, Jacobson KA. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1999;42:706–721
  28. Wadsak W, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar K, et al. Preparation and first evaluation of [F-18]FE@SUPPY: a new PET tracer for the adenosine A3 receptor. Nucl Med Biol. 2008;35:61–66
  29. Melman A, Wang B, Joshi BV, Gao ZG, de Castro S, Heller CL, et al. Selective A3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem. 2008;16:8546–8556
  30. Szajek LP, Kao CHK, Kiesewetter DO, Sassaman MB, Lang L, Plascjak P, et al. Semi-remote production of Br-76 and preparation of high specific activity radiobrominated pharmaceuticals for PET studies. Radiochim Acta. 2004;92:291–295
  31. Kao CHK, Sassaman MB, Szajek LP, Ma Y, Waki A, Eckelman WC. The sequential syntheses of [Br-76]FBAU 3′,5′-dibenzoate and [Br-76]FBAU. J Labelled Compd Radiopharm. 2001;44:889–898
  32. Bradford MM. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem. 1976;72:248–254
  33. Cheng Y, Prusoff WH. Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108
  34. Jeong LS, Choe SA, Gunaga P, Kim HO, Lee HW, Lee SK, et al. Discovery of a new nucleoside template for human A3 adenosine receptor ligands: d-4′-thioadenosine derivatives without 4′-hydroxymethyl group as highly potent and selective antagonists. J Med Chem. 2007;50:3159–3162
  35. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, et al. Comparative pharmacology of human adenosine receptor subtypes — characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998;357:1–9
  36. Yaar R, Jones MR, Chen JF, Ravid K. Animal models for the study of adenosine receptor function. J Cell Physiol. 2005;202:9–20
  37. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:364–374
  38. Wong CH, Cheng CY. The blood–testis barrier: its biology, regulation, and physiological role in spermatogenesis. Curr Top Dev Biol. 2005;71:263–296

PII: S0969-8051(08)00205-9

doi: 10.1016/j.nucmedbio.2008.10.003

Nuclear Medicine and Biology
Volume 36, Issue 1 , Pages 3-10 , January 2009

Article Tools

* Image Usage & Resolution